Special Report: Dimerix has received the upfront payment of US$30 million (~A$48m) from Amicus Therapeutics after signing an ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

Agents that target NaV1.8, a voltage-gated sodium channel, are showing promise. The FDA approved one of them, Journavx ...

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

Recently approved medications for resistant hypertension, uncomplicated UTIs and menopausal hot flashes show potential as ...

We want you to take advantage of everything Clinical Advisor has to offer. To view unlimited content, log in or register for free.

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

Vitamin D supplementation during pregnancy was not associated with any effects on maternal bone mineral density at 4-year follow-up.

Doctors say for diseases like measles or polio, they argue it may be wrong to withhold vaccines from people in a placebo group when those vaccines have already been shown to be effective.

The FDA has approved Rinvoq (upadacitinib), a Janus kinase inhibitor, for the treatment of adults with giant cell arteritis.